Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paula Jimenez is active.

Publication


Featured researches published by Paula Jimenez.


Oncología (Barcelona) | 2006

Tratamiento adyuvante en pacientes diagnosticados de carcinoma no microcítico de pulmón: estado de la evidencia científica

E. Esteban; Noemi Villanueva; Isabel Muñiz; M. Luque; Paula Jimenez; Beatriz Llorente; Marta Capelan; Pilar Blay; Joaquin Fra; Yolanda Fernández; Jose María Vieitez; Enrique Estrada; J. M. Buesa; Á. Jiménez Lacave

Surgery is the current treatment of choice in patients with early-stage non-small cell lung cancer. Based on the high rates of recurrence, additional local and systemic treatments have been developed, aimed at improving the cure rates. The comparative studies about the benefits of post-operative adjuvant chemotherapy and/or radiotherapy, and the meta-analysis studies made during the last decades, reviewed in some articles appeared in 95 and 97, did not confirm a significant improvement of the overall survival. Since then, new comparative trials carried out with a higher number of patients and with more active and standard chemotherapy seem to show a benefit of the administration of platinum-based chemotherapy, although it has not gained general acceptance. More recently, a new meta-analysis, that included the previous studies, has confirmed an overall increase of 4 % in survival of patients treated by surgery and adjuvant chemotherapy, especially in stages II-III patients receiving schedules of cisplatin and vinorelbine. Further studies are needed to determine the real therapeutic value of other agents, as uracil-tegafur and radiotherapy.


Oncología (Barcelona) | 2006

Tratamiento anti-hormonal adyuvante en mujeres post-menopáusicas con diagnóstico de carcinoma de mama

E. Esteban; Yolanda Fernández; Isabel Muñiz; Noemi Villanueva; M. Luque; Paula Jimenez; Beatriz Llorente; M. Capellán; A. Jiménez Lacave

Over the recent decades, tamoxifen has been considered the standard adjuvant treatment of postme-nopausal women with hormone-receptor positive breast cancer based on its capacity to reduce the annual breast cancer death. More recently, several major randomized controlled trials carried out with three different new aromatase inhibitors used either from the time of primary surgery or after 2-3 or 5 years of adjuvant tamoxifen therapy have shown a significant improvement in disease-free survival with respect to tamoxifen therapy. The described treatment-related side effects suggest different profiles of toxicity. Musculoskeletal disorders and cardiovascular events are the most serious side effects associated with the use of aromatase inhibitors, as well as the thromboembolic events and endometrial abnormalities are associated with tamoxifen therapy. An optimal treatment strategy for aromatase inhibitors administration, interventions to prevent or alleviate treatment-related side effects and identification of women at higher risk having more benefit with aromatase inhibitors need to be addressed.


Journal of Clinical Oncology | 2004

Cisplatin plus gemcitabine with or without vinorelbine as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer. Results of a randomised study of the Grupo Oncologico del Norte de Espana

E. Esteban; Noemi Villanueva; Isabel Muñiz; J. De Sande; Joaquin Fra; Yolanda Fernández; Jose María Vieitez; M. Luque; Paula Jimenez; J. Buesa; A. J. Lacave

7121 The combinations of cisplatin (C) with gemcitabine (G) and/or vinorelbine (V) have shown to be effective and safe regimens in the first line treatment of NSCLC. This study has been designed to detect a 25% increase in objective response measured by CT scan with the triplet combination (CGV) with respect to cisplatin/gemcitabine combination (CG) administered as neo-adjuvant therapy in patients with radically-treatable stage III NSCLC. With 80% of power and one-sided 5% significant level, the simple size required to confirm this hypothesis is 75 evaluable patients in each arm of treatment. Patients (pts) ≤ 75 years old, Karnofsky index ≥ 70% and adequate haematological, renal and hepatic function are stratified by stage (IIIA versus IIIB) and randomly assigned to: C 50 mg/m2 i.v. and G 1250 mg/m2 i.v. d1 and d8 alone (CG) or in combination with V 25 mg/m 2 i.v. d1 and d8 (CGV) both regimens every 3 weeks for 3 consecutive cycles followed by definitive local treatment (LT). From December 1999 to December 2005, a hundred and forty-nine pts have been randomised (CG/CGV); median age 58/58; median Karnofsky index 80/80; stage IIIA 24/26; stage IIIB 51/48; squamous 37/39; adenocarcinoma 31/32; anaplastic 7/3. Major haematological toxicities grade 3-4 were (CG/CGV; %); Anaemia (5/5) neutropenia (31/34); thrombocytopenia (4/5). Two pts in CG (2.7%) and 4 in CGV arm (5.5%) developed neutropenic fever. Major non-haematological toxicities grade 2-3 were: N/Vomiting (31/32) and fatigue (12/20). Global recurrences have been registered in 57% and 54% of pts treated with CG and CGV arm respectively. Exclusive local/ distant failure (%) has been 16/23 in CG and 23/18 in CGV arm. Preliminary results show similar high efficacy associated with moderate toxicity in both groups of treatment. The study is continuing. [Table: see text] No significant financial relationships to disclose.


Investigational New Drugs | 2008

Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study

E. Esteban; Noemi Villanueva; Isabel Muñiz; Yolanda Fernández; Joaquin Fra; M. Luque; Paula Jimenez; Beatriz Llorente; Marta Capelan; Jose María Vieitez; Enrique Estrada; J. Buesa; Angel Jiménez-Lacave


Lung Cancer | 2007

Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.

E. Esteban; Jose-Luis de Sande; Noemi Villanueva; Norberto Corral; Isabel Muñiz; José Ma Vieitez; Joaquin Fra; Yolanda Fernández; Enrique Estrada; José-Luis Fernandez; M. Luque; Paula Jimenez; Beatriz Mareque; Marta Capellan; José Ma Buesa; A. J. Lacave


Investigational New Drugs | 2011

Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.

Emilio Esteban González; Noemi Villanueva; Joaquin Fra; Jose Pablo Berros; Paula Jimenez; M. Luque; Isabel Muñiz; Pilar Blay; Yolanda Fernández; Jose María Vieitez; C. Muriel; Miguel F. Sanmamed; Pablo Pardo Coto; M. Izquierdo; Enrique Estrada; A. J. Lacave


Journal of Clinical Oncology | 2006

Prospective randomised phase II study of gemcitabine and vinorelbine versus gemcitabine and docetaxel combination in patients with previously untreated advanced non-small cell lung cancer

Yolanda Fernández; E. Esteban; Noemi Villanueva; Joaquin Fra; Isabel Muñiz; Paula Jimenez; M. Luque; Jose María Vieitez; E. Estrada; A. J. Lacave; J. M. Buesa


Journal of Clinical Oncology | 2017

Analysis of the p38MAPK pathway in the prognosis of patients with surgically resected stage I-II NSCLC.

Pablo Pardo-Coto; Emilio Esteban; Aurora Astudillo; Jose Manuel Gracia; Norberto Corral; Marta Izquierdo Manuel; Carolina Muriel Lopez; Miguel F. Sanmamed; Eduardo Gutierrez Restrepo; Miguel Valle Pereda; Carlos Fernández; Quionia Pérez Arnillas; Jose Pablo Berros Fombella; Paula Jimenez; Jose Maria Vieitez de Prado; Joaquin Fra


Journal of Clinical Oncology | 2017

Evaluation of safety and efficacy of somatuline autogel in combination with molecular targeted therapies (MTT) in patients with neuroendocrine tumors (NETs): Data from one Spanish cohort.

Jaume Capdevila; Isabel Sevilla; Vicente Alonso; Luis M. Antón Aparicio; Paula Jimenez; Enrique Grande; Juan José Reina; Jose Luis Manzano; Juan Domingo Alonso-Guadalajara; Pilar Alfonso


Journal of Clinical Oncology | 2017

Biweekly gemcitabine and capecitabine in heavily pretreated patients with metastatic colorectal cancer (mCRC).

Maria Del Pilar Solis Hernandez; Paula Jimenez; Laura Garcia; Carlos Fernandez; Quionia Pérez Arnillas; David Jose Rodriguez Rubi; Ana Lucrecia Ruiz; Luisa Sánchez Lorenzo; Walter Antonio Li Torres; Esther Uriol; Maria Dolores Menendez Prieto; Jose Maria Vieitez de Prado

Collaboration


Dive into the Paula Jimenez's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Buesa

University of Oviedo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jose Luis Manzano

Autonomous University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge